RxDoctor Payments Data

Molly Monroe

Medical · West Des Moines, IANPI 1598472136

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 48 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 12 manufacturers, the largest accounting for just 20.8% — the pattern of someone who eats at a lot of different presentations.

$1,293in general payments, 2019–2025

Across 48 payments — averaging $26.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • UCB, Inc.$269
  • Johnson & Johnson$188
  • AbbVie$180
  • Incyte Corporation$158
  • Lilly USA, LLC$153
  • Regeneron Healthcare Solutions, Inc.$144
  • plus $201 from 6 others

What the payments were for

  • Food & beverage$1,293100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,293 in reported general payments places this provider in the 75th percentile of 141 medical providers in Iowa.

See all medical providers in Iowa

Medicare billing

Part B allowed, 2024
$30,479
Medicare patients
87
Services billed
298

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron65$15,218
XareltoRivaroxaban12$3,385
LantusInsulin Glargine,hum.Rec.Anlog36$3,045
Potassium Chloride18$1,957
Budesonide13$1,801
Nystatin103$1,774
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen86$1,748
Pregabalin54$1,730
Fentanyl20$1,687
Gabapentin46$873
Tramadol Hcl56$786
Prazosin Hcl13$777
Oxycodone Hcl25$670
Levothyroxine Sodium46$658
Buspirone Hcl32$601

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$188$3,38512 claims
AbbVieSynthroid$180$29211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 141 medical providers in Iowa.

Other medical in West Des Moines

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →